Iliyana Petrova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Iliyana Petrova has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Alexandrov
National Heart Hospital -Sofi a Резюме
3 shared publications - Georgi Vladimirov
National Heart Hospital -Sofi a Резюме
3 shared publications - Hristo Mateev
Interventional Cardiology Department National Heart Hospital MU-Sofia Sofia Bulgaria
3 shared publications - Iva Paskaleva
Laboratory Department, National Heart Hospital, 65 Konioviza Str., 1309 Sofia, Bulgaria
2 shared publications - Ivaylo Bogov
Central hospitalier Châlons-en-Champagne, 51 Rue du Commandant Derrien, 51000 Châlons-en-Champagne, France
2 shared publications - Nina Gotcheva
Department of Cardiology, MHAT “National Cardiology Hospital” EAD, Sofia, Bulgaria (N.G.).
2 shared publications
Latest Publications
- Open Access
- 22 April 2026
- Published by IMR Press in Journal of Integrative Neuroscience
- Vol. 25 (4) , 49628
Lipid Ratio Biomarkers as Protective Factors for Depressive Symptoms in Newly Diagnosed Metabolic Syndrome: Evidence From Regression Modeling
Background: Obesity and depression have a bidirectional relationship. Previous work has shown that obesity increases the risk of depression, while atypical depression can elevate the risk of obesity. This study aimed to investigate the associations between anthropometric markers, lipid and insulin resistance biomarkers, inflammatory cytokines, and adipokines with depressive symptom severity in individuals with newly diagnosed metabolic syndrome (MetS). Methods: 88 treatment-naïve adults with newly identified MetS, without known coronary artery disease, were included. Clinical assessments comprised anthropometric measures, while laboratory analyses measured lipid metabolism markers, insulin resistance indicators, inflammatory cytokines, and adipokines. Depressive symptom severity was assessed using the von Zerssen Depression Scale (DS), validated for the Bulgarian population. To explore latent structures within biomarker domains, principal component analyses (PCA) were performed. Associations between depressive symptoms and biomarkers were then examined in two steps: first, using linear regression with PCA-derived component scores, and second, through hierarchical multiple regression focusing on selected individual biomarkers, controlling for covariates such as age and gender. Results: PCA identified distinct latent structures within anthropometric, lipid, insulin resistance, and cytokine domains, though regression analyses using PCA-derived component scores did not yield significant associations with depressive symptoms (all p > 0.050). Hierarchical multiple regression with selected biomarkers showed that lower low-density lipoprotein cholesterol (LDLc)/Apolipoprotein B (ApoB) ratios were consistently associated with higher depressive symptom severity (Model 1: β = –0.332, p = 0.011; Model 2: β = –0.326, p = 0.012; Model 3: β = –0.319, p = 0.013), while higher interleukin-6 (IL-6) levels were independently linked to greater symptom severity (Model 1: β = 0.217, p = 0.052; Model 3: β = 0.230, p = 0.033). ApoB/apolipoprotein A1 (ApoA1) ratios and age showed weaker or non-significant effects. Conclusions: LDLc/ApoB ratio and IL-6 levels are independently associated with depressive symptom severity in newly diagnosed MetS, highlighting their potential as clinically relevant biomarkers. These findings highlight perspectives for integrating lipid and inflammatory profiles in the assessment of depression risk within MetS populations.
- 22 April 2026
- Published by IMR Press in Journal of Integrative Neuroscience
- Vol. 25 (4) , 49628
Open AccessLipid Ratio Biomarkers as Protective Factors for Depressive Symptoms in Newly Diagnosed Metabolic Syndrome: Evidence From Regression Modeling
Background: Obesity and depression have a bidirectional relationship. Previous work has shown that obesity increases the risk of depression, while atypical depression can elevate the risk of obesity. This study aimed to investigate the associations between anthropometric markers, lipid and insulin resistance biomarkers, inflammatory cytokines, and adipokines with depressive symptom severity in individuals with newly diagnosed metabolic syndrome (MetS). Methods: 88 treatment-naïve adults with newly identified MetS, without known coronary artery disease, were included. Clinical assessments comprised anthropometric measures, while laboratory analyses measured lipid metabolism markers, insulin resistance indicators, inflammatory cytokines, and adipokines. Depressive symptom severity was assessed using the von Zerssen Depression Scale (DS), validated for the Bulgarian population. To explore latent structures within biomarker domains, principal component analyses (PCA) were performed. Associations between depressive symptoms and biomarkers were then examined in two steps: first, using linear regression with PCA-derived component scores, and second, through hierarchical multiple regression focusing on selected individual biomarkers, controlling for covariates such as age and gender. Results: PCA identified distinct latent structures within anthropometric, lipid, insulin resistance, and cytokine domains, though regression analyses using PCA-derived component scores did not yield significant associations with depressive symptoms (all p > 0.050). Hierarchical multiple regression with selected biomarkers showed that lower low-density lipoprotein cholesterol (LDLc)/Apolipoprotein B (ApoB) ratios were consistently associated with higher depressive symptom severity (Model 1: β = –0.332, p = 0.011; Model 2: β = –0.326, p = 0.012; Model 3: β = –0.319, p = 0.013), while higher interleukin-6 (IL-6) levels were independently linked to greater symptom severity (Model 1: β = 0.217, p = 0.052; Model 3: β = 0.230, p = 0.033). ApoB/apolipoprotein A1 (ApoA1) ratios and age showed weaker or non-significant effects. Conclusions: LDLc/ApoB ratio and IL-6 levels are independently associated with depressive symptom severity in newly diagnosed MetS, highlighting their potential as clinically relevant biomarkers. These findings highlight perspectives for integrating lipid and inflammatory profiles in the assessment of depression risk within MetS populations.
- Open Access
- 7 April 2023
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 29 (1) , 86-93
Percutaneous coronary interventions in patients over 80 years old age with acute coronary syndrome
Age is an important non-modifi able risk factor for cardiovascular disease. Both European and American guidelines recommend offering an invasive reperfusion strategy in elderly patients with ACS, taking into account the patients‘ comorbidities and baseline level of functioning. Materials and methods: All patients over 80 years of age with acute coronary syndrome, treated in the Department of Invasive Cardiology of the National Heart Hospital for the period between January 1, 2016. and December 31, 2018, are retrospectively analyzed. The primary endpoint was defi ned as all-cause mortality during the hospital stay and at follow-up. Predictors of mortality were assessed and independent predictors were identifi ed. Results: During the study period, 179 patients aged 80 years or older were identifi ed as being treated for ACS with PCI. In the study population, in hospital mortality for the index event was 11.8%. At a mean follow-up time of 20.19 ± 11.9 months, mortality rose signifi cantly to 64.6%. When evaluating in-hospital mortality on multivariate analysis, the two independent predictors were Cardiogenic shock (HR 0.005, 95% CI 0.01–0.44; p < 0.001) and acute/exacerbated renal failure (0.986 95% CI 0.984-0.997; p = 0.015). Conclusion: The present study provides important information regarding characteristics and outcomes in very elderly patients undergoing PCI for ACS. In the future, this subset of patients is predicted to grow, meaning that their approach must be evidence-based to ensure safe and effective treatment options.
- 7 April 2023
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 29 (1) , 86-93
Open AccessPercutaneous coronary interventions in patients over 80 years old age with acute coronary syndrome
Age is an important non-modifi able risk factor for cardiovascular disease. Both European and American guidelines recommend offering an invasive reperfusion strategy in elderly patients with ACS, taking into account the patients‘ comorbidities and baseline level of functioning. Materials and methods: All patients over 80 years of age with acute coronary syndrome, treated in the Department of Invasive Cardiology of the National Heart Hospital for the period between January 1, 2016. and December 31, 2018, are retrospectively analyzed. The primary endpoint was defi ned as all-cause mortality during the hospital stay and at follow-up. Predictors of mortality were assessed and independent predictors were identifi ed. Results: During the study period, 179 patients aged 80 years or older were identifi ed as being treated for ACS with PCI. In the study population, in hospital mortality for the index event was 11.8%. At a mean follow-up time of 20.19 ± 11.9 months, mortality rose signifi cantly to 64.6%. When evaluating in-hospital mortality on multivariate analysis, the two independent predictors were Cardiogenic shock (HR 0.005, 95% CI 0.01–0.44; p < 0.001) and acute/exacerbated renal failure (0.986 95% CI 0.984-0.997; p = 0.015). Conclusion: The present study provides important information regarding characteristics and outcomes in very elderly patients undergoing PCI for ACS. In the future, this subset of patients is predicted to grow, meaning that their approach must be evidence-based to ensure safe and effective treatment options.
- Open Access
- 20 March 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (6) , 1180
NGAL as Biomarker of Clinical and Subclinical Damage of Kidney Function after Coronary Angiography
Contrast-induced acute kidney injury (CI-AKI) is a serious complication after angiographic examinations in cardiology. Diagnosis may be delayed based on standard serum creatinine, and subclinical forms of kidney damage may not be detected at all. In our study, we investigate the clinical use in these directions of a “damage”-type biomarker—neutrophil gelatinase-associated lipocalin (NGAL). Among patients with a high-risk profile undergoing scheduled coronary angiography and/or angioplasty, plasma NGAL was determined at baseline and at 4th and 24th h after contrast administration. In the CI-AKI group, NGAL increased significantly at the 4th hour (Me 109.3 (IQR 92.1–148.7) ng/mL versus 97.6 (IQR 69.4–127.0) ng/mL, p = 0.006) and at the 24th hour (Me 131.0 (IQR 81.1–240.8) ng/mL, p = 0.008). In patients with subclinical CI-AKI, NGAL also increased significantly at the 4th hour (Me 94.0 (IQR 75.5–148.2) ng/mL, p = 0.002) and reached levels close to those in patients with CI-AKI. Unlike the new biomarker, however, serum creatinine did not change significantly in this group. The diagnostic power of NGAL is extremely good—AUC 0.847 (95% CI: 0.677–1.000; p = 0.001) in CI-AKI and AUC 0.731 (95% CI: 0.539–0.924; p = 0.024) in subclinical CI-AKI. NGAL may be a reliable biomarker for the early diagnosis of clinical and subclinical forms of renal injury after contrast angiographic studies.
- 20 March 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (6) , 1180
Open AccessNGAL as Biomarker of Clinical and Subclinical Damage of Kidney Function after Coronary Angiography
Contrast-induced acute kidney injury (CI-AKI) is a serious complication after angiographic examinations in cardiology. Diagnosis may be delayed based on standard serum creatinine, and subclinical forms of kidney damage may not be detected at all. In our study, we investigate the clinical use in these directions of a “damage”-type biomarker—neutrophil gelatinase-associated lipocalin (NGAL). Among patients with a high-risk profile undergoing scheduled coronary angiography and/or angioplasty, plasma NGAL was determined at baseline and at 4th and 24th h after contrast administration. In the CI-AKI group, NGAL increased significantly at the 4th hour (Me 109.3 (IQR 92.1–148.7) ng/mL versus 97.6 (IQR 69.4–127.0) ng/mL, p = 0.006) and at the 24th hour (Me 131.0 (IQR 81.1–240.8) ng/mL, p = 0.008). In patients with subclinical CI-AKI, NGAL also increased significantly at the 4th hour (Me 94.0 (IQR 75.5–148.2) ng/mL, p = 0.002) and reached levels close to those in patients with CI-AKI. Unlike the new biomarker, however, serum creatinine did not change significantly in this group. The diagnostic power of NGAL is extremely good—AUC 0.847 (95% CI: 0.677–1.000; p = 0.001) in CI-AKI and AUC 0.731 (95% CI: 0.539–0.924; p = 0.024) in subclinical CI-AKI. NGAL may be a reliable biomarker for the early diagnosis of clinical and subclinical forms of renal injury after contrast angiographic studies.
- Open Access
- 4 January 2023
- Published by MDPI AG in Preprints.org
NGAL as Biomarker of Clinical and Subclinical Damage of Kidney Function after Coronary Angiography
Contrast-induced acute kidney injury (CI-AKI) is a serious complication after angiographic examinations in cardiology. Diagnosis may be delayed based on standard serum creatinine, and subclinical forms of kidney damage may not be detected at all. In our study we investigate the clinical use in these directions of a “damage” type biomarker - Neutrophil Gelatinase-Associated Lipocalin (NGAL). Among patients with a high-risk profile undergoing scheduled coronary angiography and/or angioplasty, plasmsa NGAL was determined at baseline, at 4 and 24 hours after contrast administration. In the CI-AKI group, NGAL increased significantly at the 4th hour (132.33±72.83 ng/ml versus 111.48±65.06 ng/ml, p=0.006) and at the 24th hour (212 .93±276.61 ng/ml, p=0.008). In patients with subclinical CI-AKI, NGAL also increased significantly at the 4th hour (128.18±99 ng/ml, p=0.002) and reached levels close to those in patients with CI-AKI. Unlike new biomarker, however, serum creatinine did not change significantly in this group. The diagnostic power of NGAL is extremely good - AUC 0.847 (95% CI: 0.677-1.000; p=0.001) in CI-AKI and AUC 0.731 (95% CI: 0.539 – 0.924; p=0.024) in subclinical CI-AKI. NGAL may be a reliable biomarker for early diagnosis of clinical and subclinical forms of renal injury after contrast angiographic studies.
- 4 January 2023
- Published by MDPI AG in Preprints.org
Open AccessNGAL as Biomarker of Clinical and Subclinical Damage of Kidney Function after Coronary Angiography
Contrast-induced acute kidney injury (CI-AKI) is a serious complication after angiographic examinations in cardiology. Diagnosis may be delayed based on standard serum creatinine, and subclinical forms of kidney damage may not be detected at all. In our study we investigate the clinical use in these directions of a “damage” type biomarker - Neutrophil Gelatinase-Associated Lipocalin (NGAL). Among patients with a high-risk profile undergoing scheduled coronary angiography and/or angioplasty, plasmsa NGAL was determined at baseline, at 4 and 24 hours after contrast administration. In the CI-AKI group, NGAL increased significantly at the 4th hour (132.33±72.83 ng/ml versus 111.48±65.06 ng/ml, p=0.006) and at the 24th hour (212 .93±276.61 ng/ml, p=0.008). In patients with subclinical CI-AKI, NGAL also increased significantly at the 4th hour (128.18±99 ng/ml, p=0.002) and reached levels close to those in patients with CI-AKI. Unlike new biomarker, however, serum creatinine did not change significantly in this group. The diagnostic power of NGAL is extremely good - AUC 0.847 (95% CI: 0.677-1.000; p=0.001) in CI-AKI and AUC 0.731 (95% CI: 0.539 – 0.924; p=0.024) in subclinical CI-AKI. NGAL may be a reliable biomarker for early diagnosis of clinical and subclinical forms of renal injury after contrast angiographic studies.